Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed endometrial hyperplasia,~* D-score \> 0,~* Age 30-70 years,~* No contra-indications against progestin hormones,~* Written consent,~* Patients who have been treated with transcervical resection need a histologically confirmed diagnosis of hyperplasia taken after the TCR~Exclusion Criteria:~* D-score \< 0,~* Age \< 30 or \> 70,~* Increased sensitivity to progestins,~* Pregnancy,~* Infection or cancer in genitalia or mammary gland,~* Liver disease,~* Serious thrombophlebitis.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MPA 10 mg per oral cyclic for 6 months (Type: ACTIVE_COMPARATOR): The peroral treatment is used 10 days each month
- MPA 10 mg per os continuous 6 months (Type: ACTIVE_COMPARATOR): Per oral MPA 10 mg is taken daily for 6 months
- LNG-IUD for 6 months (Type: ACTIVE_COMPARATOR): Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).